Welcome to our dedicated page for Ispecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on Ispecimen stock.
iSpecimen Inc. (NASDAQ: ISPC) generates a steady flow of company-specific news that reflects both its role in life science research and its activities in the capital markets. Public announcements consistently describe iSpecimen as an online global marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with hospitals, labs, biobanks, blood centers and other healthcare providers that have access to patients and specimens needed for medical discovery.
News related to ISPC frequently covers financing and capital-raising transactions. Recent press releases describe underwritten public offerings, private placements of common stock and pre-funded warrants, and the issuance of preferred stock, along with intended uses of proceeds such as marketing, working capital, and payments under agreements with service providers and technology partners. These items are often accompanied by references to related SEC filings, such as registration statements on Form S-1 and current reports on Form 8-K.
Operational and strategic updates form another key category of iSpecimen news. The company has announced initiatives to expand services for high-demand cancer biospecimens, including plans to pursue partnerships with U.S.-based cancer centers and to act as a preferred provider of cancer biospecimens in collaboration with an international genomic sequencing partner. Other releases highlight the company’s ability to secure suppliers for specimens related to emerging infectious diseases, such as human metapneumovirus, illustrating how its marketplace can respond to evolving research needs.
Technology and infrastructure developments are also prominent in iSpecimen’s news flow. The company has reported milestones in a digital transformation program powered by the Salestack platform, describing the installation of modern, cloud-native infrastructure to enhance the iSpecimen Marketplace. In addition, iSpecimen has issued detailed announcements about a corporate treasury strategy focused on digital assets and the Solana blockchain ecosystem, including advisory relationships with WestPark Capital and BlockArrow.
Governance and listing-related disclosures appear in both press releases and SEC-linked news, such as notices from Nasdaq regarding listing standards, special and annual stockholder meetings, and leadership changes at the executive and board levels. Together, these updates provide investors and researchers with insight into iSpecimen’s marketplace activities, strategic direction, financing plans, and regulatory interactions. Visitors to the ISPC news page can review this evolving record of announcements to understand how the company is positioning its biospecimen marketplace and managing its public-company obligations.
iSpecimen reported strong financial results for Q3 2021, with revenue increasing by 21% to $2.7 million, driven by expanding sales efforts and a growing user base. The company's nine-month revenue surpassed $8.6 million, a 57% increase compared to 2020. Notably, unique suppliers increased to 197 and registered users in the marketplace grew 30% year-over-year. Despite increasing general and administrative expenses to $1.7 million, the net loss reduced to approximately $1.1 million. iSpecimen aims to broaden its offerings and enhance its technology moving forward.
iSpecimen Inc. (Nasdaq: ISPC) announces participation in two virtual conferences in November 2021: A.G.P.'s Biotech & Specialty Pharma Conference on November 10 and the 12th Annual Craig-Hallum Alpha Select Conference on November 16. These events will provide opportunities for one-on-one meetings with management. iSpecimen specializes in connecting life scientists to human biospecimens through a unique online marketplace and cloud-based technology, enhancing medical discovery efforts. For more details, visit www.ispecimen.com.
iSpecimen Inc. (NASDAQ: ISPC) will announce its third quarter financial results on November 4, 2021, before market open. The conference call is scheduled for 8:30 a.m. ET, featuring remarks from CEO Christopher Ianelli, CFO Tracy Curley, and COO Jill Mullan. Interested individuals can join the call via toll-free numbers or access a replay until November 18, 2021. The company provides an online marketplace for human biospecimens, connecting scientists with healthcare providers for medical research.
iSpecimen Inc. (Nasdaq: ISPC) announced an expansion of its human biospecimen supplier network to enhance the availability of whole blood, plasma, and biofluids for liquid biopsy development. This move aims to support a growing market projected to reach $1.45 billion with a 24% annual growth rate through 2026. The company has supplied thousands of biospecimens for nearly 30 studies, reinforcing its commitment to advancing liquid biopsy technology, which offers less invasive disease detection methods.
iSpecimen Inc. (Nasdaq: ISPC) announced its inclusion in the Russell Microcap Index, effective September 20, 2021. This inclusion signifies recognition of the company's growth in the biospecimen procurement sector, expected to enhance visibility within the investment community. Being part of the Russell indexes, which benchmark approximately $10.6 trillion in assets, positions iSpecimen favorably for attracting institutional investors. The company is also refining its iSpecimen Marketplace, aiming to support researchers in scientific discovery.
iSpecimen (Nasdaq: ISPC), a leader in the online marketplace for human biospecimens, announced CEO Christopher Ianelli will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, occurring virtually from September 13-15, 2021. His presentation will be available on-demand starting September 13 at 7:00 a.m. ET. iSpecimen connects life scientists with healthcare providers through its innovative platform to facilitate medical discovery.
iSpecimen Inc. (ISPC) announced a growth in its cancer-related supplier network despite challenges posed by COVID-19. The company formed partnerships with various labs and biobanks, significantly enhancing access to tissue and biofluid specimens from cancer patients. A recent collaboration with a European healthcare organization adds 17 types of cancer specimens, expanding the network to over 30 suppliers. These developments are aimed at improving specimen availability for cancer research, supporting advancements in therapies and diagnostics.
iSpecimen Inc. (Nasdaq: ISPC) announced that CEO Dr. Christopher Ianelli will be interviewed on The RedChip Money Report® on Bloomberg TV, airing at 7 p.m. ET on August 14, 2021. This program reaches approximately 73 million homes in the U.S. and offers insights on small-cap investing and interviews with industry leaders. The company provides an online marketplace for human biospecimens, linking life scientists with healthcare providers through its cloud-based technology. More details are available at www.ispecimen.com.
iSpecimen Inc. (ISPC) reported a 93% revenue growth year-over-year, reaching $2.9 million for Q2 2021. The company completed its IPO, raising approximately $18.2 million in net proceeds. It also expanded its registered research users by 40%, totaling over 3,800. However, iSpecimen experienced a net loss of approximately $1.4 million, attributed to increased operating expenses post-IPO. The company aims to enhance its marketplace capabilities while addressing rising costs from specimen procurement.
iSpecimen (Nasdaq: ISPC) has enhanced its custom biofluids collection service to deliver urgently needed research samples faster to life sciences organizations. Originally developed during COVID-19, this service allows researchers, particularly in the Boston area, to receive direct blood draws and saliva samples within hours. CEO Christopher Ianelli emphasized that this service aims to meet ongoing demands for fresh specimens, thus supporting medical research effectively. Additionally, iSpecimen invites Boston-area individuals to donate biospecimens for research purposes.